EFSA’s experts concluded that more research is
needed to confirm these results from human studies. Studies
on workers exposed to acrylamide in the workplace show an
increased risk of disorders to the nervous system.
Is there a “tolerable dose” of acrylamide?
Acrylamide and its metabolite glycidamide are genotoxic
and carcinogenic. Since any level of exposure to a genotoxic
substance could potentially damage DNA and lead to cancer,
EFSA’s scientists conclude that they cannot set a tolerable daily
intake (TDI) of acrylamide in food.
Instead, EFSA’s experts estimated the dose range within which
acrylamide is likely to cause a small but measurable tumour
incidence (called “neoplastic” effects) or other potential adverse
effects (neurological, pre- and post-natal development and
male reproduction). The lower limit of this range is called the
Benchmark Dose Lower Confidence Limit (BMDL10).
▶ For tumours, experts selected a BMDL10 of 0.17mg/kg bw/
day 1
.
▶ For other effects, neurological changes were seen as the
most relevant with a BMDL10 of 0.43 mg/kg bw/day.
By comparing the BMDL10 to human dietary exposure to
acrylamide, scientists can indicate a “level of health concern”
known as the margin of exposure.
1 mg/kg bw/day = milligrams per kilogram of body weight per day
Attached Files
-
acrylamide150604en.pdf 1.56MB
42 downloads
-
817e.pdf 1.1MB
45 downloads
